专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09611474B2 Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof 有权
公开(公告)号：US09611474B2
公开(公告)日：2017-04-04
申请号：US14426513
申请日：2013-09-12
申请人： Quark Pharmaceuticals, Inc.
发明人： Elena Feinstein , Sharon Avkin-Nachum , Hagar Kalinski , Igor Mett
IPC分类号： C07H21/04 , C12N15/113
CPC分类号： C12N15/113 , C12N15/1135 , C12N15/1136 , C12N2310/14 , C12N2310/317 , C12N2310/319 , C12N2310/321 , C12N2310/3521 , C12N2320/30
摘要： Provided herein are double stranded nucleic acid molecules, compositions comprising same and methods of use thereof for the treatment of a subject wherein expression of DDIT4 is associated with the etiology or progression of a disease or disorder in the subject. The compounds are preferably chemically synthesized and modified dsRNA molecules.

2. 发明授权

US09932578B2 Double-stranded oligonucleotide molecules to P53 and methods of use thereof 有权
公开(公告)号：US09932578B2
公开(公告)日：2018-04-03
申请号：US14421845
申请日：2013-09-12
申请人： QUARK PHARMACEUTICALS, INC.
发明人： Elena Feinstein , Sharon Avkin-Nachum , Hagar Kalinski , Igor Mett
IPC分类号： C12N15/11 , C12N15/113
CPC分类号： C12N15/113 , C12N15/1135 , C12N15/1136 , C12N2310/14 , C12N2310/317 , C12N2310/319 , C12N2310/321 , C12N2310/3521 , C12N2320/30
摘要： The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.

3. 发明申请

US20160215284A1 COMPOSITIONS AND METHODS FOR TREATING LUNG DISEASE AND INJURY 有权
标题翻译：用于治疗肺部疾病和伤害的组合物和方法
公开(公告)号：US20160215284A1
公开(公告)日：2016-07-28
申请号：US14924993
申请日：2015-10-28
申请人： Quark Pharmaceuticals Inc. , Washington University
发明人： Andrew E. Gelman , Elena Feinstein , Svetlana Adamsky , Igor Mett , Hagar Kalinski , Sharon Avkin-Nachum
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/321 , C12N2310/344 , C12N2310/3521
摘要： Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising down-regulating the TLR2 gene or both the TLR2 gene and TLR4 gene. Provided herein are compositions, methods and kits for treating lung diseases, disorders and injury.
摘要翻译：本文公开了治疗哺乳动物肺疾病，病症和损伤的治疗方法，包括治疗急性呼吸窘迫综合征（ARDS），急性肺损伤，肺纤维化（特发性），博来霉素诱导的肺纤维化，机械通气机诱导的肺损伤，慢性阻塞性肺疾病（COPD），慢性支气管炎，肺气肿，肺移植后闭塞性细支气管炎和肺移植引起的急性移植物功能障碍，包括治疗，预防或预防原发性移植物衰竭，缺血再灌注损伤，再灌注损伤，再灌注水肿，同种异体移植物功能障碍，肺再植入反应，肺移植后闭塞性细支气管炎和/或器官移植后的原发性移植物功能障碍（PGD），特别是肺移植，包括下调TLR2基因或TLR2基因和TLR4基因。本文提供了用于治疗肺部疾病，病症和损伤的组合物，方法和试剂盒。

4. 发明申请

US20150361430A1 METHODS FOR TREATING EYE DISORDERS 有权
公开(公告)号：US20150361430A1
公开(公告)日：2015-12-17
申请号：US14837366
申请日：2015-08-27
申请人： Quark Pharmaceuticals, Inc.
发明人： Elena Feinstein , Evgenia Alpert , Igor Mett , Amir Bar-Ilan , Igor Spivak , Hagar Kalinski , Natanja Slager
IPC分类号： C12N15/113 , A61K9/00
CPC分类号： C12N15/113 , A61K9/0048 , C12N2310/11 , C12N2310/14 , C12N2320/30
摘要： The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.

5. 发明申请

US20150267194A1 DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF 有权
标题翻译： DDD4的双链寡核苷酸分子及其使用方法
公开(公告)号：US20150267194A1
公开(公告)日：2015-09-24
申请号：US14426513
申请日：2013-09-12
申请人： QUARK PHARMACEUTICALS, INC.
发明人： Elena Feinstein , Sharon Avkin-Nachum , Hagar Kalinski , Igor Mett
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/1135 , C12N15/1136 , C12N2310/14 , C12N2310/317 , C12N2310/319 , C12N2310/321 , C12N2310/3521 , C12N2320/30
摘要： Provided herein are double stranded nucleic acid molecules, compositions comprising same and methods of use thereof for the treatment of a subject wherein expression of DDIT4 is associated with the etiology or progression of a disease or disorder in the subject. The compounds are preferably chemically synthesized and modified dsRNA molecules.
摘要翻译：本文提供了双链核酸分子，包含其的组合物及其用于治疗受试者的方法，其中DDIT4的表达与受试者的疾病或病症的病因或进展相关。化合物优选是化学合成和修饰的dsRNA分子。

6. 发明申请

US20150203845A1 DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO P53 AND METHODS OF USE THEREOF 有权
标题翻译：双链寡核苷酸分子与P53的结合及其使用方法
公开(公告)号：US20150203845A1
公开(公告)日：2015-07-23
申请号：US14421845
申请日：2013-09-12
申请人： QUARK PHARMACEUTICALS, INC.
发明人： Elena Feinstein , Sharon Avkin-Nachum , Hagar Kalinski , Igor Mett
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/1135 , C12N15/1136 , C12N2310/14 , C12N2310/317 , C12N2310/319 , C12N2310/321 , C12N2310/3521 , C12N2320/30
摘要： The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.
摘要翻译：本申请涉及核酸化合物，包含其的组合物及其用于治疗各种疾病，病症和病症的方法。所述化合物优选是化学合成的和修饰的双链核酸分子，其下调p53基因的表达。

7. 发明申请

US20180044671A9 DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO P53 AND METHODS OF USE THEREOF 有权
公开(公告)号：US20180044671A9
公开(公告)日：2018-02-15
申请号：US14421845
申请日：2013-09-12
申请人： QUARK PHARMACEUTICALS, INC.
发明人： Elena Feinstein , Sharon Avkin-Nachum , Hagar Kalinski , Igor Mett
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/1135 , C12N15/1136 , C12N2310/14 , C12N2310/317 , C12N2310/319 , C12N2310/321 , C12N2310/3521 , C12N2320/30
摘要： The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.

8. 发明授权

US09701961B2 Methods for treating eye disorders 有权
公开(公告)号：US09701961B2
公开(公告)日：2017-07-11
申请号：US14837366
申请日：2015-08-27
申请人： Quark Pharmaceuticals, Inc.
发明人： Elena Feinstein , Evgenia Alpert , Igor Mett , Amir Bar-Ilan , Igor Spivak , Hagar Kalinski , Natanja Slager
IPC分类号： C12N15/113 , A61K9/00
CPC分类号： C12N15/113 , A61K9/0048 , C12N2310/11 , C12N2310/14 , C12N2320/30
摘要： The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.

9. 发明申请

US20160333356A1 OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR PATHWAY 审中-公开
标题翻译：类似受体途径的寡核苷酸调节剂
公开(公告)号：US20160333356A1
公开(公告)日：2016-11-17
申请号：US15222695
申请日：2016-07-28
申请人： QUARK PHARMACEUTICALS, INC.
发明人： ELENA FEINSTEIN , Svetlana Adamsky , Sharon Avkin-Nachum , Hagar Kalinski , Igor Mett
IPC分类号： C12N15/113
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/317 , C12N2310/3183 , C12N2310/32 , C12N2320/51 , C12N2310/321 , C12N2310/3521
摘要： Disclosed herein are double stranded nucleic acid molecules and pharmaceutical compositions comprising same useful in the treatment of, inter alia, acute and chronic inflammation, neuropathic pain, primary graft dysfunction (PGD) after lung transplantation in a subject in need thereof. The compounds are preferably chemically synthesized and modified dsRNA compounds, which down regulate or inhibit expression of Toll like receptor 4.
摘要翻译：本文公开的是双链核酸分子和药物组合物，其包含用于治疗急性和慢性炎症，神经性疼痛，有需要的受试者肺移植后的原发性移植物功能障碍（PGD）的特征。化合物优选是化学合成和修饰的dsRNA化合物，其下调或抑制Toll样受体4的表达。

10. 发明授权

US09121020B2 Methods for treating eye disorders 有权
标题翻译：治疗眼睛疾病的方法
公开(公告)号：US09121020B2
公开(公告)日：2015-09-01
申请号：US14217079
申请日：2014-03-17
申请人： QUARK PHARMACEUTICALS, INC.
发明人： Elena Feinstein , Evgenia Alpert , Igor Mett , Hagar Kalinski , Amir Bar-Ilan , Igor Spivak , Natanja Slager
IPC分类号： C12N15/11 , C12N15/113 , A61K9/00
CPC分类号： C12N15/113 , A61K9/0048 , C12N2310/11 , C12N2310/14 , C12N2320/30
摘要： The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.
摘要翻译：本发明涉及用于抑制受试者中视网膜神经节细胞损失的组合物和方法，包括非侵入性地施用于受试者眼睛表面的眼科组合物，其包含治疗有效量的至少一种siRNA，其下调与视网膜神经节细胞丧失相关的靶基因的表达，从而抑制受试者中视网膜神经节细胞的丧失。本发明的方法还涉及具有下调哺乳动物眼睛中视网膜组织中表达的人类基因表达的结构基序的化学修饰的siRNA化合物的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式